Device/Diagnostics Quarterly Deal Statistics, Q3 2013
A look at financing, M&A, and alliance activity, July–September 2013
Executive Summary
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
You may also be interested in...
NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
Up Close With Russian Investor Rusnano: A Q&A With Anatoly Chubais
In 2007, the Russian government committed $10 billion to invest in nanotechnology. About half of that has been invested, with little to show for it so far. After a recent shake-up, Rusnano is looking to prove itself and attract the private investors that could allow it eventually to privatize.
Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.